This clinical trial tests the impact of tear fluid in detecting tumor-associated extracellular vesicles (TEVs) in patients with glioblastoma. Brain tumors release small particles, called TEVs, that may provide information about the tumor, including how it responds to treatment. These particles can be found in cerebrospinal fluid (CSF), which is the fluid that surrounds the brain and spinal cord. Collecting CSF can be difficult and expensive, especially if samples are needed frequently to track these particles over time. Tear fluid is easier to collect than spinal fluid. If tears are found to contain similar tumor-related particles, changes in the tumor may be tracked by studying the particles found in tear fluid.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07775534.
Locations matching your search criteria
United States
California
Duarte
City of Hope Comprehensive Cancer CenterStatus: Approved
Contact: Lisa Anne Feldman
Phone: 626-218-8680
PRIMARY OBJECTIVE:
I. To assess the feasibility of tear collection from healthy control and glioblastoma (GBM) patients (Phase 1 and 2).
SECONDARY OBJECTIVES:
I. To assess the feasibility of isolating and analyzing tumor-associated extracellular vesicles (TEVs) from tears of GBM patients (Phase 1 and 2).
II. To characterize the composition of tear-derived extracellular vesicles (EVs).
EXPLORATORY OBJECTIVES:
I. To compare EV profiles between patients with GBM and healthy control participants (Phase 1 and 2).
II. To explore longitudinal changes in EV profiles of patients from tears, CSF and plasma (Phase 2), and their association with clinical disease status, including radiographic response and recurrence.
III. To explore concordance between EV profiles and matched tumor molecular pathology as determined by HopeSeq analysis (Phase 2).
OUTLINE: Patients are assigned to 1 of 2 phases.
PHASE 1: Patients and healthy controls undergo collection of tears on study.
PHASE 2: Patients and healthy controls undergo collection of tears and blood samples and patients undergo collection of standard of care CSF samples throughout the study.
After completion of study intervention, patients are followed for up to 2 years.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationCity of Hope Comprehensive Cancer Center
Principal InvestigatorLisa Anne Feldman